Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?

authors:

avatar Mohamad Amin Pourhoseingholi 1 , avatar Sara Ashtari 1 , avatar Seyed Moayed Alavian ORCID 2 , *

Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Middle East Liver Diseases Center (MELD), Tehran, IR Iran
Hepatitis Monthly: Vol.14, issue 11; 25540
published online: November 22, 2014
article type: Editorial
received: November 21, 2014
accepted: November 22, 2014
DOI: https://doi.org/10.5812/hepatmon.25540

how to cite: Pourhoseingholi M A, Ashtari S, Alavian S M. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?. Hepat Mon. 2014;14(11):25540. https://doi.org/10.5812/hepatmon.25540.

Abstract

This article does not have abstract.

Full Text

Full text is available in PDF